Обзорная статья

MicroRNA-383: A tumor suppressor miRNA in human cancer

Abdollah JafarzadehDepartment of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman, IranMajid NooriGolestan Hospital Research Center, AJA University of Medical Sciences, Tehran, IranShaghayegh SarrafzadehDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranSeyed Saeed Tamehri ZadehSchool of Medicine, Tehran University of Medical Sciences, Tehran, IranMaryam NematiDepartment of Hematology and Laboratory Sciences, School of Para-Medicine, Kerman University of Medical Sciences, Kerman, IranNazanin ChatrabnousEndocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, IranSara JafarzadehStudent Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, IranMichael R. HamblinLaser Research Centre, Faculty of Health Science, University of Johannesburg, Johannesburg, South AfricaMohammad Hassan Jafari Najaf AbadiDepartment of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranHamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran

2022en

ABI

Аннотация

Downregulated expression of anti-tumor miR-383 has been found in many kinds of cancer. MiR-383 family members can directly target the 3'-untranslated region (3'-UTR) of the mRNA of some pro-tumor genes to attenuate several cancer-related processes, including cell proliferation, invasion, migration, angiogenesis, immunosuppression, epithelial-mesenchymal transition, glycolysis, chemoresistance, and the development of cancer stem cells, whilst promoting apoptosis. Functionally, miR-383 operates as a tumor inhibitor miRNA in many types of cancer, including breast cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, esophageal cancer, lung cancer, head and neck cancer, glioma, medulloblastoma, melanoma, prostate cancer, cervical cancer, oral squamous cell carcinoma, thyroid cancer, and B-cell lymphoma. Both pro-tumor and anti-tumor effects have been attributed to miR-383 in ovarian cancer. However, only the pro-tumor effects of miR-383 were reported in cholangiocarcinoma. The restoration of miR-383 expression could be considered a possible treatment for cancer. This review discusses the anti-tumor effects of miR-383 in human cancers, emphasizing their downstream target genes and potential treatment approaches.

Перевод пока недоступен

Идентификаторы

DOI: 10.3389/fcell.2022.955486

Цитирования и источники

Цитирований: 3Использованных источников: 0

Показатели — AkademScholar